Abstract
The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Keywords: Antidiabetic drugs, new characteristics, new drug development, new insulins, new mechanisms of action, personalized medicine, type 2 diabetes.
Current Diabetes Reviews
Title:Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Volume: 11 Issue: 1
Author(s): Friedrich Mittermayer, Erica Caveney, Claudia De Oliveira, Loukas Gourgiotis, Mala Puri, Li-Jung Tai and J. Rick Turner
Affiliation:
Keywords: Antidiabetic drugs, new characteristics, new drug development, new insulins, new mechanisms of action, personalized medicine, type 2 diabetes.
Abstract: The global burden of type 2 diabetes is increasing worldwide, and successful treatment of this disease needs constant provision of new drugs. Twelve classes of antidiabetic drugs are currently available, and many new drugs are under clinical development. These include compounds with known mechanisms of action but unique properties, such as once-weekly DPP4 inhibitors or oral insulin. They also include drugs with new mechanisms of action, the focus of this review. Most of these compounds are in Phase 1 and 2, with only a small number having made it to Phase 3 at this time. The new drug classes described include PPAR agonists/modulators, glucokinase activators, glucagon receptor antagonists, anti-inflammatory compounds, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, apical sodium-dependent bile acid transporter (ASBT) inhibitors, SGLT1 and dual SGLT1/SGLT2 inhibitors, and 11beta- HSD1 inhibitors.
Export Options
About this article
Cite this article as:
Mittermayer Friedrich, Caveney Erica, De Oliveira Claudia, Gourgiotis Loukas, Puri Mala, Tai Li-Jung and Turner J. Rick, Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development, Current Diabetes Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573399810666141224121927
DOI https://dx.doi.org/10.2174/1573399810666141224121927 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Discovery and ADMET: Where Are We Now
Current Topics in Medicinal Chemistry Human Ascariasis: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science Pathophysiology of Sepsis and Recent Patents on the Diagnosis, Treatment and Prophylaxis for Sepsis
Recent Patents on Inflammation & Allergy Drug Discovery Effects of Kallistatin on Oxidative Stress and Inflammation on Renal Ischemia-Reperfusion Injury in Mice
Current Vascular Pharmacology Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science Decreasing Arterial Aging by Controlling Blood Pressure Levels and Hypertension: A Step Forward
Current Vascular Pharmacology Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews GHB Pharmacology and Toxicology: Acute Intoxication, Concentrations in Blood and Urine in Forensic Cases and Treatment of the Withdrawal Syndrome
Current Neuropharmacology Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Novel Antiinflammatory and Antiinfective Agents
Anti-Infective Agents in Medicinal Chemistry An Overview of Olive Oil Biomolecules
Current Biotechnology A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Herpes Simplex Virus-Induced Ocular Diseases: Detrimental Interaction Between Virus and Host
Current Immunology Reviews (Discontinued) Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Revisiting the J-curve Phenomenon. An Old New Concept?
Current Hypertension Reviews